Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.

@article{Lew1995CiprofloxacinVT,
  title={Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.},
  author={M A Lew and Kathryn Kehoe and Jerome Ritz and K H Antman and Lawrence B. Nadler and Leslie A. Kalish and Robert W. Finberg},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1995},
  volume={13 1},
  pages={
          239-50
        }
}
PURPOSE To compare the efficacy and safety of ciprofloxacin (CIP) and trimethoprim/sulfamethoxazole (TMS) for the prevention of bacterial infections in patients who received bone marrow transplantation (BMT) for the treatment of solid and hematopoietic neoplasms. PATIENTS AND METHODS Adult inpatients about to undergo BMT for lymphoma, leukemia, or solid tumors were enrolled onto a prospective, randomized, double-blinded, controlled trial that compared CIP (750 mg orally twice per day) with… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 44 CITATIONS

A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication.

  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2014